Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I received an email from IR as well about this same thing. It just said the announcement will be non market hours. They didn’t specify pre or post market.
Options expire the 3rd Friday of every month. I’m not 100% sure that’s what caused the spike, but possibly
Options
No, not unless they announce a negative decision before then. In which case it will go much lower than $4
I got nothing, if I were in their shoes it’s not how I would do it. If I knew whether the drug worked or not (and they do) I would drop Imetelstat as soon as I knew it didn’t so I could focus my effort on something else that has potential. That’s just me, not sure what they are thinking. It’s a business so guess they feel they need to take all the time they have in case something develops either positive or negative that could sway their decision.
In my opinion it will be a positive decision, but who knows at this point.
Hi Jeff, can you enlighten me as to why on earth the shorts would be shorting this stock at this time considering all the positives. And they are willing to pay in upwards of 50% interest to get the shares. Seems they are extreme confident that geron is going down.
For what it’s worth, I’m no expert, but common sense wise I totally agree with you. Between the job postings listing Imetelstat, adding the drug to compassionate use and all these JnJ/Jansen execs liking and sharing the article, it seems like if JnJ dropped Imetelstat now it would constitute investor manipulation/fraud.
What I’m so confused about is why list Imetelstat on the compassionate use list on sept 4th and remove it a little over a week later.
Based upon what I have read, the continuation announcement will come from geron because it is a material event for them, not JNJ. The way i see it, that means if we hear nothing from geron today, then why would we hear much about Imetelstat tomorrow from JnJ? This isn’t meant as a negative, just wondering
Sorry for your loss, curious if your family member had access to Imetelstat?
I just wanted to hear his perspective, it’s clear he couldn’t really answer my question because all of his reasons are false based upon the info we have been given.
Google, I think others have asked you this question previously, not sure if you have given a legit answer. I am wondering if you can honestly explain why you don’t think geron and Imetelstat will succeed? Also why don’t you think JnJ will elect to continue? Just trying to understand you perspective as I want to learn all I can both positive and negative to make a good decision. I look at all the data/info that is right in front of our faces and cant see why JnJ would let Imetelstat slip through their fingers. Thanks
Google Take a Dump....question for you. Do you believe that Jansen is going to go the conference in June and present negative information regarding Imetelstat?
I agree, this rally is strange. Feels like manipulation of some sort because there is no real news, other than the conference in June. Is it possible that geron is releasing shares again?
I still believe Jansen will elect to continue and that will cause the share price to go up quite a bit. Not as much as we were all hoping, but still higher than it is now.
Like I said, believe what you want. I am about an honest a person as you will find. I could copy and paste the email, but what does that prove, nothing! It’s just text in an internet post
I’m done defending myself. IR told me they aren’t “expecting” approval for either indication in 2018. I’m sticking to it. Doesn’t mean it won’t happen, but at this time based upon the data they have, they aren’t expecting it. End of story!
For sure, things can change.
Well take this for what it’s worth, believe me or don’t, could care less.
I received a response back from IR regarding FDA approval for MDS. They don’t expect approval in 2018 for MDS either.
She left it out of my email as well. I sent another asking about MDS approval. Will report back if I get a response
I am wondering about MDS though. Could Imetelstat be approved for MDS this year? She has only told me no for MF.
This was proven to be misinformation. PFS was added in September 2017.
Tom I believe you. She has told me the same thing. People on this board refuse to believe this isn’t happening this year. Not saying the future isn’t potentially bright, but this is a long term deal
So Imetelstat wont be FDA approved this year like everyone has been saying it would?
I’d be happy as heck with 12-15 per share. Still not sure a buyout will happen.
Man we are all going to be sticking rich. First I heard $30 per share, then $100, now $700 per share. I may as well just quit my job tomorrow.
It is on their Facebook page I believe. I have also emailed their investor relations and they said they are “targeting to release specifics” about a partnership by end of Q2. Not exactly sure what this means. Will they be announcing an actual partnership or just announcing what the plan is.
So BPMX has indicated that they plan to announce a partnership by end of Q2. So that means we should have news by the end of June?
It’s sideways time for gern until September
Thanks! I do have patience and that is precisely the point I’m trying to make. FDA approval ain’t happening this year folks. I hope I’m wrong because that means there is a good chance I’m filthy rich this year. But not betting on it like all the kool-aid drinkers out there.
It is not a lie, believe what you want i guess. I’m an honest person. Email them yourself and see if you get a different answer
If that’s the case and people have been alive for 3yrs taking Imetelstat then why is it not approved yet? Makes a guy wonder....is there something negative that we don’t know?
I am supportive and positive about the future for Geron. But I’m realistic, there will be no buyout or fda approval this year.
Well in my email correspondence with Geron investor relations they indicated to me that they didn’t believe the fast track status would allow Imetelstat to be approved this year. To me that isn’t very fast.
So why doesn’t the FDA get on with approval then
2018 to 2021, not just 2018. If it was truly 2018 I’d be excited as h$ll. I don’t believe this is coming to an end in 2018. Going to have to endure several more years of this BS in my opinion.
I don’t know what to think. It’s hard to know who is correct most of what we read is speculation. Personally I feel like it’s one or the other. Both aren’t correct. I’m holding onto my shares, but honestly it’s not going to be easy. Going to take a lot of patience and guts to hold until the end. Hoping I’m up to the challenge and it pays off.
Some interesting posts on Imetelchat you may want to read.
Not sure, I basically asked if there is any language in the current agreement that could prevent a buyout from another pharmaceutical and they said there is not. I’ll see if I can reword the question and get an answer to your question
I agree, I’m fairly new to investing and what I’ve learned is nobody knows much of anything. Days when people are saying the price is going to go up, it goes down and vice versa. Every comment you read is speculation. I invested in GERN with the idea that I could make some decent money this yr. Kind of thinking now I may have to hold for a year or 2 longer to see this to the end. But who knows, may wake up one morning with buyout news. Hoping and praying for the best!
I have emailed investor relations at Geron and they told me there is no language in the current agreement with JnJ that would prevent another pharmaceutical company from out bidding JnJ during a buyout. I am being totally honest about this. It came directly from Geron investor relations.
That might be true, but if JnJ play it conservative again and tries a lowball offer like they must have done with Pharmacyclics I could see another pharma swooping in with a higher bid.
There is nothing in the current agreement to prevent it from happening. Personally I’m not sure it will come to a buyout, but if it does and Geron gets bought for $8-$10 per share it will be an embarrassment if Imetelstat truly works as advertised.